Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization

Leukemia

Volumn 16, Issue 12, 2002, Pages 2395-2399

  Muller M C ^a   Merx, K ^a   Weisser A ^a   Kreil, S ^a   Lahaye, T ^a   Hehlamann, R ^a   Hochhaus, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chronic myelogenous leukemia; Minimal residual disease; Quantitative RT PCR; RNA stabilization

Indexed keywords

BCR ABL PROTEIN; CESIUM CHLORIDE; EDETIC ACID; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; IMATINIB; MESSENGER RNA; RNA;

ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; BLOOD STORAGE; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITY GRADIENT CENTRIFUGATION; DIAGNOSTIC KIT; FEASIBILITY STUDY; HUMAN; INTERMETHOD COMPARISON; LEUKOCYTE; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PHLEBOTOMY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA DEGRADATION; RNA EXTRACTION; RNA STABILITY; RNA TRANSCRIPTION; ROOM TEMPERATURE; SENSITIVITY ANALYSIS; STANDARD;

EID: 0036936826     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402734     Document Type: Article

References (19)

1. Szczepanski T, Orfao A, van der Velden V, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol 2001; 2: 409-417.
2. Hochhaus A, Weisser A, La Rosée P, Emig M, Müller MC, Saussele S, Reiter A, Kuhn C, Berger U, Hehlmann R, Cross NC. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 2000; 14: 998-1005.
3. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Parreira A, Gameiro P, Diaz MG, Malec M, Langerak AW, San Miguel JF, Biondi A. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
4. Cross NC, Feng L, Bungey J, Goldman JM. Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. Leuk Lymphoma 1993; 11 (Suppl. 1): 39-43.
5. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002; 16: 53-59.
6. Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8: 186-189.
7. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NC, Hochhaus A. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825-1832.
8. Mannhalter C, Koizar D, Mitterbauer G. Evaluation of RNA isolation methods and reference genes for RT-PCR analyses of rare target RNA. Clin Chem Lab Med 2000; 38: 171-177.
9. Burmeister T, Maurer J, Aivado M, Elmaagacli AH, Grunebach F, Held KR, Hess G, Hochhaus A, Hoppner W, Lentes KU, Lubbert M, Schafer KL, Schafhausen P, Schmidt CA, Schuler F, Seeger K, Seelig R, Thiede C, Viehmann S, Weber C, Wilhelm S, Christmann A, Clement JH, Ebener U, Enczmann J, Leo R, Schleuning M, Schoch R, Thiel E. Quality assurance in RT-PCR-based BCR/ABL diagnostics - results of an interlaboratory test and a standardization approach. Leukemia 2000; 14: 1850-1856.
10. Weisser A, La Rosée P, Burmeister T, Raff T, Kneba M, Hehlmann R, Hochhaus A. Sensitivity, quality and comparability of BCR-ABL quantification by RT-PCR: results of an interlaboratory analysis. Blood 2001; 98 (Suppl. 1): 320a.
11. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
12. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.
13. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000; 95: 62-66.
14. Weisser A, La Rosee P, Paschka P, Kuhn C, Müller MC, Hehlmann R, Hochhaus A. Sample preparation as important factor for detection of minimal residual disease in CML by Real-Time PCR. Onkologie 2000; 23 (Suppl. 7): 97 (Abstr.).
15. Pahl A, Brune K. Gene expression changes in blood after phlebotomy: implications for gene expression profiling. Blood 2002; 100: 1094-1095.
16. Sachs AB. Messenger RNA degradation in eukaryotes. Cell 1993; 74: 413-421.
17. Beelman CA, Parker R. Degradation of mRNA in eukaryotes. Cell 1995; 81: 179-183.
18. Brennan CM, Steitz JA. HuR and mRNA stability. Cell Mol Life Sci 2001; 58: 266-277.
19. Florell SR, Coffin CM, Holden JA, Zimmermann JW, Gerwels JW, Summers BK, Jones DA, Leachman SA. Preservation of RNA for functional genomic studies: a multidisciplinary tumor bank protocol. Mod Pathol 2001; 14: 116-128.